Cite
HARVARD Citation
Graybill, W. et al. (n.d.). 13 Efficacy on individualized starting dose (ISD) and fixed starting dose (FSD) of niraparib per investigator-assessment (IA) in newly diagnosed advanced ovarian cancer (OC). International journal of gynecological cancer. p. A10. [Online].